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We report here the complete genome sequence of the human gut symbiont Roseburia hominis A2-183T (DSM 16839T
NCIMB 14029T), isolated from human feces. The genome is represented by a 3,592,125-bp chromosome with 3,405 coding se-
quences. A number of potential functions contributing to host-microbe interaction are identified.
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One of the most proficient butyrate producers in the humangut is Roseburia hominis A2-183, which produces up to
20 mM of butyrate (1). In ulcerative colitis (UC) the numbers
of R. hominis are significantly lower compared to control (2, 3).
Its use for nutritional/medical applications has been pro-
posed (D. Kelly, 13 August 2014, WO Patent App. PCT/
GB2012/052,495), and it has received an orphan drug designa-
tion for UC (http://www.accessdata.fda.gov/scripts/opdlisting
/oopd/OOPD_Results_2.cfm?Index_Number439114). Flagel-
lins from this bacterium are potent immunomodulators (D. Kelly,
A. Patterson, E. Monnais, I. Mulder, 16 October 2014,WOPatent
App. PCT/GB2014/051,123).We sequenced and annotated its ge-
nome to reveal beneficial properties.
The strain was grown as described before (4). Chromosomal
DNA was isolated using an UltraClean Microbial DNA isolation
kit (MoBio Laboratories) and a Wizard Genomic DNA purifica-
tion kit (Promega); 1.5- to 3.5-kb fragments were cloned using the
CloneSmart LCAmp kit (Lucigen), 4- to 8-kb fragments using
the pJAZZ-OC vector (Lucigen), and 40-kb fragments using the
CopyControl fosmid library production kit (Epicentre Biotech-
nologies). End reads were obtained by Sanger sequencing.
Genomic DNA was sequenced using 454 GS20/454 FLX sequenc-
ers. Reads were assembled using MIRA 3 (http://chevreux.org
/projects_mira.html). The RAST (5) and Prokaryotic Genome (6)
pipelines were used for annotation and comparative genomics.
The strain harbors a single circular genome of 3,592,125 bp,
with a GC content of 48.5%. We identified 3,285 genes, 3,143
potential protein-encoding sequences, 4 ribosomal operons with
12 rRNA genes, and 57 tRNA genes. The largest gene counts be-
longed to carbohydrate metabolism (17.6%), biosynthesis of
amino acids and derivatives (10.8%), and protein metabolism
(10.7%). Comparative genomics identified Roseburia inuliniv-
orans,Roseburia intestinalis, and Eubacterium rectale as closest rel-
atives, which is consistent with their close phylogenetic relation-
ship (7).
R. hominis produces butyrate via the acetyl-CoA pathway. The
pathway genes are found at four locations: (i) acetyl-CoA acetyl-
transferase, 3-hydroxybutyryl-CoA dehydrogenase, and butyryl-
CoA dehydrogenase, including electron transfer protein  and 
subunits; (ii) enoyl-CoA hydratase and butyryl-CoA dehydroge-
nase, including electron transfer protein  and  subunits; (iii)
3-hydroxybutyryl-CoA dehydratase; and (iv) 4-hydroxybutyrate
coenzyme A transferase. The genes for conversion of 3-hydroxy
butanoyl-CoA to crotonyl-CoA to butyryl-CoA are present in two
nonidentical copies. This contributes to the enhanced butyrate
production by eliminating bottlenecks in the conversion of acetyl-
CoA to butyrate.
The CRISPR-Cas system in this bacterium includes a 33-bp
consensus direct repeat GTCGCTCCCTGTGAGGGGAGCGTG
GATTGAAATwith 82 spacers, with a total length of 6,582 bp. The
large number of spacers foundmaybe due to its symbiotic nature:
there is a negative correlation between the number of repeats and
pathogenic potential (8, 9). CRISPR-Cas acts as a barrier against
the gene influx including virulence genes.
Flagellin signaling via TLR5 protects against chemicals, bacte-
ria, viruses, and radiation (10, 11), while its inhibition results in
spontaneous colitis (12). Four different flagellin genes present in
the genome, but only one resideswithin the flagellar operon, while
the others are located in regions unrelated to flagellar motility.
This increased gene dose may contribute to the immunomodula-
tory and protective properties of this bacterium.
Nucleotide sequence accession number. The genome of
R. hominis A2-183 has been deposited in GenBank under the ac-
cession number CP003040.
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